Brisbane, Calif.-based biotech firm XDx Inc. on Wednesday announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock.
XDx specializes in molecular diagnostics for the monitoring of transplant rejection and autoimmune diseases.
Drivers be warned: If you’re looking to circumvent Oak Street traffic to… Continue reading
BART’s South Hayward station is closed Tuesday afternoon after a fatality aboard… Continue reading
Gary Delagnes-endorsed candidate to challenge Tony Montoya for presidency
Immigrants rights advocates with Bay Resistance, Coalition to Close the Concentration Camps… Continue reading
Half a century after activists occupied Alcatraz in a historic movement for… Continue reading
